AU2019206958A1 - PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof - Google Patents

PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof Download PDF

Info

Publication number
AU2019206958A1
AU2019206958A1 AU2019206958A AU2019206958A AU2019206958A1 AU 2019206958 A1 AU2019206958 A1 AU 2019206958A1 AU 2019206958 A AU2019206958 A AU 2019206958A AU 2019206958 A AU2019206958 A AU 2019206958A AU 2019206958 A1 AU2019206958 A1 AU 2019206958A1
Authority
AU
Australia
Prior art keywords
antibody
antigen
binding fragment
pharmaceutical use
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019206958A
Other languages
English (en)
Inventor
Jinming Gu
Xiaoling GU
Qiyue Hu
Jiahua JIANG
Weikang Tao
Lei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of AU2019206958A1 publication Critical patent/AU2019206958A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019206958A 2018-01-10 2019-01-09 PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof Pending AU2019206958A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810023267 2018-01-10
CN201810023267.0 2018-01-10
PCT/CN2019/070982 WO2019137397A1 (fr) 2018-01-10 2019-01-09 Anticorps pd-l1, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée

Publications (1)

Publication Number Publication Date
AU2019206958A1 true AU2019206958A1 (en) 2020-07-16

Family

ID=67219311

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019206958A Pending AU2019206958A1 (en) 2018-01-10 2019-01-09 PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof

Country Status (12)

Country Link
US (1) US11359021B2 (fr)
EP (1) EP3741777A4 (fr)
JP (1) JP2021510078A (fr)
KR (1) KR20200108306A (fr)
CN (1) CN111278861B (fr)
AU (1) AU2019206958A1 (fr)
BR (1) BR112020013475A2 (fr)
CA (1) CA3087105A1 (fr)
MX (1) MX2020007406A (fr)
TW (1) TWI717678B (fr)
WO (1) WO2019137397A1 (fr)
ZA (1) ZA202004907B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2727914C2 (ru) * 2015-11-17 2020-07-24 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
CN110760517B (zh) * 2019-10-09 2022-04-29 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
WO2022121846A1 (fr) * 2020-12-08 2022-06-16 博际生物医药科技(杭州)有限公司 Anticorps se liant au pd-l1 et son application
TWI789679B (zh) * 2021-01-12 2023-01-11 大陸商江蘇先聲藥業有限公司 抗人程序性死亡配體-1（pd-l1）的抗體及其用途
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
CN116178545A (zh) * 2021-09-24 2023-05-30 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
CN115925937A (zh) * 2022-08-05 2023-04-07 赛灵药业科技集团股份有限公司北京分公司 一种抗体或其片段及其制药用途
CN115785269B (zh) * 2022-11-01 2023-09-22 四川大学 抗pd-l1的抗体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
CA3016482A1 (fr) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research Nouvelle molecule immunoregulatrice b7-h1,
KR101411165B1 (ko) * 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
MX349463B (es) * 2008-09-26 2017-07-31 Univ Emory Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
PE20120341A1 (es) * 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
EP3192811A1 (fr) 2009-02-09 2017-07-19 Université d'Aix-Marseille Anticorps pd-1 et pd-l1 et leurs utilisations
MX343747B (es) * 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
BR122022015975B1 (pt) 2012-05-15 2024-01-02 Bristol-Myers Squibb Company Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo
EP3553086A1 (fr) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Protéines de liaison à un antigène se liant à pd-l1
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
CA3139031A1 (fr) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
KR20230070054A (ko) * 2013-03-15 2023-05-19 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US20160089434A1 (en) 2013-06-03 2016-03-31 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
WO2015048520A1 (fr) 2013-09-27 2015-04-02 Genentech, Inc. Formulations d'anticorps anti-pdl1
CA2956399A1 (fr) * 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anticorps anti-pd-l1
CN105777906B (zh) 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
US10336824B2 (en) 2015-03-13 2019-07-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
CN106243225B (zh) * 2015-06-11 2021-01-19 智翔（上海）医药科技有限公司 新型抗-pd-l1抗体
RU2727914C2 (ru) 2015-11-17 2020-07-24 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
CN107216389B (zh) * 2016-03-18 2022-03-29 和迈生物科技有限公司 抗pd-l1纳米抗体及其编码序列和用途
SG11201809336QA (en) * 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
CN106699891B (zh) * 2017-01-25 2019-04-09 北京天广实生物技术股份有限公司 一种抗pd-l1抗体、其药物组合物及其用途
CN107365383B (zh) * 2017-07-12 2019-04-30 苏州大学附属第一医院 一种人源化抗人pd-1单克隆抗体及其制备方法、用途与药物
WO2019129136A1 (fr) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anticorps anti-pd-l1 et ses applications

Also Published As

Publication number Publication date
RU2020124261A3 (fr) 2022-01-25
US11359021B2 (en) 2022-06-14
KR20200108306A (ko) 2020-09-17
ZA202004907B (en) 2022-10-26
EP3741777A4 (fr) 2021-10-13
TW201930360A (zh) 2019-08-01
TWI717678B (zh) 2021-02-01
JP2021510078A (ja) 2021-04-15
CN111278861A (zh) 2020-06-12
CN111278861B (zh) 2022-05-27
BR112020013475A2 (pt) 2020-12-08
EP3741777A1 (fr) 2020-11-25
WO2019137397A1 (fr) 2019-07-18
CA3087105A1 (fr) 2019-07-18
US20200339692A1 (en) 2020-10-29
RU2020124261A (ru) 2022-01-25
MX2020007406A (es) 2020-09-14

Similar Documents

Publication Publication Date Title
AU2019206958A1 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
SG10201804945WA (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2021011489A (es) Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
MX2017012965A (es) Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
EP3737421A4 (fr) Procédés de production, purification et formulation de conjugués anticorps-médicaments
EP4067387A4 (fr) Anticorps bispécifique anti-pd-1-anti-vegfa, composition pharmaceutique et leur utilisation
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
WO2020132658A3 (fr) Tubulysines et conjugués tubulysines-protéines
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2021002531A (es) Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
EP3647323A4 (fr) Anticorps anti-gitr, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée
EP4006055A4 (fr) Anticorps anti-bcma, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée